Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty

Schousboe JT, Brown GA

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.2106/JBJS.L.00400

Indexing Status
Subject indexing assigned by NLM

MeSH
Age Factors; Aged; Aged, 80 and over; Anticoagulants /economics /therapeutic use; Arthroplasty, Replacement /adverse effects /economics; Aspirin /economics /therapeutic use; Cost-Benefit Analysis; Female; Fibrinolytic Agents /economics /therapeutic use; Heparin, Low-Molecular-Weight /economics /therapeutic use; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Venous Thromboembolism /drug therapy /economics /etiology /prevention & control

AccessionNumber
22013031534

Date bibliographic record published
30/10/2013